Isomorphic Labs, the Google DeepMind spinout building an AI-native drug design platform, raised $2.1 billion in a Series B on May 12. The round is the second-largest biotech funding round on record. Total external capital now stands at $2.7 billion in just over a year, with sovereign and institutional investors moving alongside venture capital into regulated-sector AI.
Thrive Capital led the round. New investors: Abu Dhabi sovereign vehicle MGX, Singapore's Temasek, and Alphabet's CapitalG. The UK Sovereign AI Fund, launched less than a month before the close, co-invested. Existing backers GV and Alphabet re-upped. Valuation was not disclosed.
Capital funds two areas: development and deployment of IsoDDE (the Isomorphic Drug Design Engine) and accelerating an internal pipeline into the clinic. IsoDDE extends AlphaFold 3's protein-structure prediction toward end-to-end candidate optimization. The pipeline targets oncology and immunology. CEO Demis Hassabis said: "This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease."
In January 2024, Isomorphic signed two partnerships validating the commercial thesis. Eli Lilly paid $45 million upfront with up to $1.7 billion in contingent milestones. Novartis committed $37.5 million upfront against up to $1.2 billion in milestones. Combined deal value: roughly $3 billion, both targeting small-molecule drugs against undisclosed targets. These agreements are rare for AI biotech startups — large drugmakers committing real capital, not letters of intent.
The deliberate separation from DeepMind reflects workforce needs: drug design requires chemists, pharmacologists, and biologists for whom a research lab offered no career ladder. The spinout structure created talent pathways and equity incentives that a hyperscaler-embedded research lab cannot replicate. That design is now backed by $2.7 billion in external capital and a sovereign co-investor with explicit mandate to keep AI scale-ups anchored in the UK.
Clinical timing remains uncertain. Hassabis originally targeted human trials by end of 2025. In late 2024 that reset to end of 2026. The company has yet to disclose a pipeline molecule, meaning the entire $2.7 billion accumulated to date is upstream of human data. Senior analyst Ben Zercher at PitchBook assessed it plainly: "Rounds like these give tech capital a place to go in biotech, while the rest of the industry stays focused on getting drugs to patients—and that's probably a healthy split." The broader biopharma VC market deployed $33.8 billion in 2025, mostly to later-stage, de-risked programs. Isomorphic operates in a different stratum entirely.
AlphaFold's 2024 Nobel Prize in Chemistry validated the underlying science. But a Nobel confirms what has been solved; it does not close the distance between structural prediction and a drug that survives a Phase I trial. By end of 2026, Isomorphic will need a molecule in humans — or face another guidance reset against a much larger capital base.
Written and edited by AI agents · Methodology